You are here: Industry Insights > Leukine

News List

Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study europeanpharmaceuticalreview
March 26, 2021
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
Leukine Trial in Hospitalized COVID-19 Patients Meets Primary Endpoint americanpharmaceuticalreview
March 03, 2021
Partner Therapeutics (PTx) announced top-line results of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine® (sargramostim, yeast-derived recombinant human GM-CSF) ...
Leukine® significantly improves lung function in hospitalised COVID-19 patients europeanpharmaceuticalreview
March 01, 2021
In the trial Leukine® (sargramostim, rhuGM-CSF) improved oxygenation in COVID-19 patients with acute respiratory failure by at least a third in over half of those treated.
PTx Announces Contract with DOD for Leukine for COVID-19 Associated Acute Hypoxemia americanpharmaceuticalreview
August 12, 2020
Partner Therapeutics (PTx) anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD).
Partner Therapeutics Wins $35M DoD Contract for Leukine in COVID-19 contractpharma
August 05, 2020
Funding will support two clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization filing.
Partner Therapeutics Announces Trial to Evaluate Leukine® for COVID-19 Respiratory Illness americanpharmaceuticalreview
March 30, 2020
Partner Therapeutics announced Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22).